Business Context and Reporting Period
Cardio Diagnostics Holdings, Inc. (CDIO), a Delaware corporation, filed this Form 8-K on June 19, 2023. The filing reports the entry into a Material Definitive Agreement regarding the compensation and terms of service for its independent directors.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to director compensation:
- Annual Retainer: $50,000 per independent director.
- Payment Method: Restricted Stock Units (RSUs).
- Vesting Schedule (2023): $25,000 on June 30, $12,500 on September 30, and $12,500 on December 31.
- Travel Allowance: $500 cash per diem for out-of-town travel.
- Share Price Determination: The number of shares issuable is indeterminable at this time and will be based on the closing stock price on each vesting date.
Material Changes
The Company entered into a Board of Directors Agreement with independent directors James Intrater, Stanley Lau, MD, Oded Levy, and Brandon Sim. This agreement formalizes their service terms, indemnification rights, and the specific RSU-based compensation structure effective for the current term.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on business outlook, or discussion of specific risks or contingencies beyond the standard representations regarding conflicts of interest and compliance with laws included in the Directors Agreement.
Investor Verification Checklist
- Verify the exact number of RSUs issued upon the June 30, 2023 vesting date based on the closing stock price.
- Confirm the total dilution impact of the $50,000 annual retainers for all four independent directors.
- Review the full text of the Directors Agreement (Exhibit 10.1) for specific indemnification clauses and conflict of interest provisions.
- Monitor future filings for any revisions to the per diem policy or expense reimbursement approvals.